Literature DB >> 11567826

Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone.

S A Snyder1, J L Lanzen, R D Braun, G Rosner, T W Secomb, J Biaglow, D M Brizel, M W Dewhirst.   

Abstract

PURPOSE: To test the feasibility of hyperglycemic reduction of oxygen consumption combined with oxygen breathing (O(2)), to improve tumor oxygenation. METHODS AND MATERIALS: Fischer-344 rats bearing 1 cm R3230Ac flank tumors were anesthetized with Nembutal. Mean arterial pressure, heart rate, tumor blood flow ([TBF], laser Doppler flowmetry), pH, and pO(2) were measured before, during, and after glucose (1 or 4 g/kg) and/or O(2).
RESULTS: Mean arterial pressure and heart rate were unaffected by treatment. Glucose at 1 g/kg yielded maximum blood glucose of 400 mg/dL, no change in TBF, reduced tumor pH (0.17 unit), and 3 mm Hg pO(2) rise. Glucose at 4 g/kg yielded maximum blood glucose of 900 mg/dL, pH drop of 0.6 unit, no pO(2) change, and reduced TBF (31%). Oxygen tension increased by 5 mm Hg with O(2). Glucose (1 g/Kg) + O(2) yielded the largest change in pO(2) (27 mm Hg); this is highly significant relative to baseline or either treatment alone. The effect was positively correlated with baseline pO(2), but 6 of 7 experiments with baseline pO(2) < 10 mm Hg rose above 10 mm Hg after combined treatment.
CONCLUSION: We demonstrated the feasibility of combining hyperglycemia with O(2) to improve tumor oxygenation. However, some cell lines are not susceptible to the Crabtree effect, and the magnitude is dependent on baseline pO(2). Additional or alternative manipulations may be necessary to achieve more uniform improvement in pO(2).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567826     DOI: 10.1016/s0360-3016(01)01654-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  A potential solution for eliminating hypoxia as a cause for radioresistance.

Authors:  Mark W Dewhirst
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

2.  Effect of a topical vasodilator on tumor hypoxia and tumor oxygen guided radiotherapy using EPR oximetry.

Authors:  Huagang Hou; Zrinka Abramovic; Jean P Lariviere; Marjeta Sentjurc; Harold Swartz; Nadeem Khan
Journal:  Radiat Res       Date:  2010-05       Impact factor: 2.841

Review 3.  Molecular radiobiology: the state of the art.

Authors:  Amato J Giaccia
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

4.  Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.

Authors:  Matthew E Hardee; Rose J Eapen; Zahid N Rabbani; Matthew R Dreher; Jeffrey Marks; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-26       Impact factor: 3.333

Review 5.  Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia.

Authors:  Simon P Robinson; John R Griffiths
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

6.  Non-invasive, simultaneous quantification of vascular oxygenation and glucose uptake in tissue.

Authors:  Narasimhan Rajaram; Andrew F Reesor; Christine S Mulvey; Amy E Frees; Nirmala Ramanujam
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 7.  Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy.

Authors:  Mark W Dewhirst; James R Oleson; John Kirkpatrick; Timothy W Secomb
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

8.  Direct arterial injection of hyperpolarized 13 C-labeled substrates into rat tumors for rapid MR detection of metabolism with minimal substrate dilution.

Authors:  Steven Reynolds; Stephen Metcalf; Edward J Cochrane; Rebecca C Collins; Simon Jones; Martyn N J Paley; Gillian M Tozer
Journal:  Magn Reson Med       Date:  2017-02-12       Impact factor: 4.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.